Phastar and Beaconcure Announce Partnership, Enhance Data Review in Clinical Trials
New agreement leverages Beaconcure’s technology to streamline review processes.
Beaconcure, a provider of artificial intelligence-enabled clinical data validation and automation, has announced a new partnership with contract research organization, Phastar. This collaboration will enhance review processes in clinical trials by leveraging Beaconcure’s technology and Phastar’s experience in the clinical data analytics domain.1
"We are thrilled to collaborate with Phastar, a leader in clinical trial analytics. By leveraging Verify, Phastar is now equipped with a collaboration platform that reduces the potential for human error and increases efficiency and transparency, enabling faster study validation and approvals,” Ilan Carmeli, chief operating officer and co-founder, Beaconcure said in a press release. “By utilizing a unified platform, teams can integrate efforts, improve data integrity, and accelerate decision-making. These enhancements enable Phastar to manage internal communications and sponsor interactions more effectively, transforming clinical reviews, shortening review cycles, and expediting the delivery of treatments."
“We at Phastar prioritize our customers' needs and continuously seek innovative solutions to ensure timely access to lifesaving treatments for patients with urgent needs. Integrating Beaconcure’s Verify platform into our processes is an impactful step and will help unlock further innovations across clinical data reporting, reviewing, and submission stages,” Ping-Chung Chang, head of business transformation and China general manager, Phastar said in the press release. “We will utilize Verify to address critical areas in clinical review with automatically generated audit trails, streamlined data reporting delivery, and optimized workflow management.”
“Through this partnership, Beaconcure and Phastar are actively engaged in exploring new standards in the industry to increase speed and compliance in clinical trials,” Christine Oliver, CEO of Beaconcure said in the press release. “By partnering with Phastar and drawing Chang’s expertise, we’re not just deploying solutions—we’re creating a dynamic system that learns and improves over time.”
Reference
1. Phastar and Beaconcure Announce Partnership to Deliver Process Revolution in Clinical Data Review. News release. May 20, 2024. Accessed May 23, 2024. https://www.businesswire.com/news/home/20240520818825/en/Phastar-and-Beaconcure-Announce-Partnership-to-Deliver-Process-Revolution-in-Clinical-Data-Review
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
